search
Back to results

Sex Differences in Risk for Alcohol Abuse

Primary Purpose

Alcohol Abuse

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Alcohol
Sponsored by
Mark Fillmore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Alcohol Abuse focused on measuring brain activation during response inhibition, BARI, fMRI, stop signal task, sex difference, menstrual, inhibitory control

Eligibility Criteria

21 Years - 29 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • heavy drinking
  • Alcohol Use Disorder Identification Test score above 7
  • right-handed
  • BMI between 19 and 26
  • high school education
  • fluent in English
  • women must have regular menstrual cycles
  • not using hormonal contraceptives

Exclusion Criteria:

  • drug use disorder (SCID, DSM-5), other than nicotine or caffeine
  • meets withdrawal criteria
  • history of physical or psychiatric disease
  • contraindication for fMRI
  • pregnant or breastfeeding
  • smoking more than 5 cigarettes per day

Sites / Locations

  • University Of Kentucky Psychology Research Lab

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Males

Females

Arm Description

Participants in this group will be adult male heavy drinkers.

Participants in this group will be adult female heavy drinkers. Data will be segregated by menstrual cycle phase - the late follicular or mid-luteal phase.

Outcomes

Primary Outcome Measures

Change in Brain Activation During Response Inhibition (BARI)
Brain activation during response inhibition (BARI) will be assessed using blood oxygenation level dependent (BOLD) fMRI during performance of the stop signal task with alcohol compared to to placebo. Values will be determined by the contrast of BOLD activation during successful inhibition trials relative to go trials.

Secondary Outcome Measures

Change in Estradiol Levels
Estradiol levels will be measured from blood samples with alcohol compared to to placebo.
Change in Progesterone Levels
Progesterone levels will be measured from blood samples with alcohol compared to to placebo.
Change in Testosterone Levels
Testosterone levels will be measured from blood samples with alcohol compared to to placebo.
Change in Biphasic Alcohol Effects Score
The Biphasic Alcohol Effects Scale (BAES) is a 14-point self-reporting, unipolar adjective rating scale designed to measure both stimulant and sedative effects of alcohol. Scores range from 0-10 for each of the 14 questions. Higher scores indicate increased stimulation or sedation. Scores will be reported with alcohol comparted to placebo.
Change in Drug Effects Questionnaire Score
Drug Effects Questionnaire (DEQ) consists of simple, face-valid, visual analog scale (VAS) questions on which people report their subjective states after ingesting a substance. The analog scale of responses ranges from "not at all" to "extremely." Scores are measured in millimeters from the scale origin. Higher scores (longer lengths) indicate greater drug effects. Scores will be reported with alcohol comparted to placebo.

Full Information

First Posted
September 2, 2020
Last Updated
August 24, 2023
Sponsor
Mark Fillmore
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
search

1. Study Identification

Unique Protocol Identification Number
NCT04543942
Brief Title
Sex Differences in Risk for Alcohol Abuse
Official Title
Neurobiological Factors Underlying Sex Differences in Risk for Alcohol Abuse
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
November 1, 2019 (Actual)
Primary Completion Date
May 24, 2023 (Actual)
Study Completion Date
May 24, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Mark Fillmore
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will determine the neural and hormonal mechanisms underlying sex differences in sensitivity to the disinhibiting effects of alcohol in heavy drinkers.
Detailed Description
Alcohol abuse inflicts enormous physical, emotional, and financial burdens on the individual and society at large. Knowing who is at risk for alcohol abuse, and why, is crucial for the development of effective prevention and treatment strategies. Alcohol abuse has been traditionally considered a male-oriented problem and as a consequence research on risk factors specific to women has been minimal. However, the sex gap in substance abuse is closing rapidly, and findings from both animal and human studies suggest that females are actually more vulnerable to drug use than males. As such, there is an urgent need to identify sex differences in risk factors for alcohol abuse in order to develop sex-specific prevention and treatment efforts. One clear candidate risk factor is poor inhibitory control, both in terms of baseline levels of inhibition and sensitivity to the disinhibiting effects of alcohol. Recent studies suggest that sex hormones affect inhibitory control in drug-free individuals, potentially contributing to sex differences in baseline levels of inhibition. However, the degree to which fluctuations in sex hormones influence sex differences in inhibition-related brain function in sober and intoxicated individuals is not known. The proposed project will determine the neural and hormonal mechanisms underlying sex differences in sensitivity to the disinhibiting effects of alcohol in heavy drinkers. The overall objective of the research is to identify hormonal determinants of alcohol effects on brain activation during response inhibition (BARI) in young adult female and male drinkers. BARI will be assessed using functional magnetic resonance imaging (fMRI) during performance of the stop signal task. This task reliably activates right-lateralized prefrontal regions implicated in inhibitory control. This study will assess BARI during IV alcohol (60mg%) and saline infusion in women during the early follicular and mid-luteal phases and in men at matched intervals.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Abuse
Keywords
brain activation during response inhibition, BARI, fMRI, stop signal task, sex difference, menstrual, inhibitory control

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Non-Randomized
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Males
Arm Type
Experimental
Arm Description
Participants in this group will be adult male heavy drinkers.
Arm Title
Females
Arm Type
Experimental
Arm Description
Participants in this group will be adult female heavy drinkers. Data will be segregated by menstrual cycle phase - the late follicular or mid-luteal phase.
Intervention Type
Drug
Intervention Name(s)
Alcohol
Other Intervention Name(s)
ethyl alcohol
Intervention Description
Alcohol will be administered by IV infusion (60mg%). Brain activation during response inhibition (BARI) will be assessed using fMRI during performance of the stop signal task.
Primary Outcome Measure Information:
Title
Change in Brain Activation During Response Inhibition (BARI)
Description
Brain activation during response inhibition (BARI) will be assessed using blood oxygenation level dependent (BOLD) fMRI during performance of the stop signal task with alcohol compared to to placebo. Values will be determined by the contrast of BOLD activation during successful inhibition trials relative to go trials.
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Change in Estradiol Levels
Description
Estradiol levels will be measured from blood samples with alcohol compared to to placebo.
Time Frame
4 weeks
Title
Change in Progesterone Levels
Description
Progesterone levels will be measured from blood samples with alcohol compared to to placebo.
Time Frame
4 weeks
Title
Change in Testosterone Levels
Description
Testosterone levels will be measured from blood samples with alcohol compared to to placebo.
Time Frame
4 weeks
Title
Change in Biphasic Alcohol Effects Score
Description
The Biphasic Alcohol Effects Scale (BAES) is a 14-point self-reporting, unipolar adjective rating scale designed to measure both stimulant and sedative effects of alcohol. Scores range from 0-10 for each of the 14 questions. Higher scores indicate increased stimulation or sedation. Scores will be reported with alcohol comparted to placebo.
Time Frame
4 weeks
Title
Change in Drug Effects Questionnaire Score
Description
Drug Effects Questionnaire (DEQ) consists of simple, face-valid, visual analog scale (VAS) questions on which people report their subjective states after ingesting a substance. The analog scale of responses ranges from "not at all" to "extremely." Scores are measured in millimeters from the scale origin. Higher scores (longer lengths) indicate greater drug effects. Scores will be reported with alcohol comparted to placebo.
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
29 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: heavy drinking Alcohol Use Disorder Identification Test score above 7 right-handed BMI between 19 and 26 high school education fluent in English women must have regular menstrual cycles not using hormonal contraceptives Exclusion Criteria: drug use disorder (SCID, DSM-5), other than nicotine or caffeine meets withdrawal criteria history of physical or psychiatric disease contraindication for fMRI pregnant or breastfeeding smoking more than 5 cigarettes per day
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Fillmore, Ph.D.
Organizational Affiliation
University of Kentucky
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Of Kentucky Psychology Research Lab
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40504
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Sex Differences in Risk for Alcohol Abuse

We'll reach out to this number within 24 hrs